论文部分内容阅读
探讨布地奈德雾化吸入治疗矽肺合并慢性阻塞性肺病的临床疗效。将2011—2013年在河北钢铁集团宣钢职工医院住院期间的矽肺合并慢性阻塞性肺病(AECOPD)的患者86例随机分为两组,观察组44例,对照组42例。采用吸氧,抗感染,支气管扩张剂,静脉糖皮质激素等常规治疗。观察组在吸氧,抗感染,支气管扩张剂治疗的基础上给予布地奈德雾化吸入替代静脉糖皮质激素,10d为1疗程,比较两组患者的临床症状、体征、动脉血氧分压(PaO2)、二氧化碳分压(PaCO2)、动脉血氧饱和度(SaO2)、第1秒最大呼气容积(FEV1)、最高呼气流量(PEF)等指标变化。结果显示,观察组总有效率高于对照组(P<0.05)。PaO2、PaCO2、SaO2、FEV1、PEF值明显升高,各项指标优于对照组,提示,布地奈德雾化吸入治疗AECOPD具有改善通气,纠正呼吸衰竭,减少并发症等功效,且药物的使用剂量小,不良反应少,效果优于静脉糖皮质激素,可作为AECOPD激素全身治疗的替代治疗。
To investigate the clinical efficacy of inhaled budesonide in the treatment of silicosis complicated with chronic obstructive pulmonary disease. Eighty-six patients with silicosis and chronic obstructive pulmonary disease (AECOPD) during hospitalization at Hebei Iron and Steel Group’s Xuan Gang Workers’ Hospital from 2011 to 2013 were randomly divided into two groups: 44 cases in the observation group and 42 cases in the control group. Adopt oxygen, anti-infection, bronchodilators, intravenous glucocorticoid and other conventional treatment. The observation group was given inhalation of budesonide instead of intravenous glucocorticoid on the basis of oxygen inhalation, anti-infective and bronchodilator treatment, and the course of treatment was 10 days. The clinical symptoms, signs, arterial partial pressure of oxygen ( PaO2, PaCO2, SaO2, FEV1, PEF and so on. The results showed that the observation group, the total effective rate was higher than the control group (P <0.05). PaO2, PaCO2, SaO2, FEV1, PEF values were significantly higher than the control group, indicating that budesonide inhalation treatment of AECOPD has the effect of improving ventilation, correct respiratory failure and reduce complications, and the use of drugs Small dose, less adverse reactions, the effect is superior to intravenous glucocorticoid, can be used as an alternative treatment of systemic AECOPD hormone therapy.